AU2006261133B2 - Therapeutic peptides and vaccines - Google Patents

Therapeutic peptides and vaccines Download PDF

Info

Publication number
AU2006261133B2
AU2006261133B2 AU2006261133A AU2006261133A AU2006261133B2 AU 2006261133 B2 AU2006261133 B2 AU 2006261133B2 AU 2006261133 A AU2006261133 A AU 2006261133A AU 2006261133 A AU2006261133 A AU 2006261133A AU 2006261133 B2 AU2006261133 B2 AU 2006261133B2
Authority
AU
Australia
Prior art keywords
peptide
hiv
binding
ccr5
dapta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006261133A
Other languages
English (en)
Other versions
AU2006261133A1 (en
Inventor
Candace Pert
Michael Ruff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAPID Pharmaceuticals AG
Original Assignee
RAPID Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RAPID Pharmaceuticals AG filed Critical RAPID Pharmaceuticals AG
Publication of AU2006261133A1 publication Critical patent/AU2006261133A1/en
Assigned to RAPID PHARMACEUTICALS AG reassignment RAPID PHARMACEUTICALS AG Request for Assignment Assignors: PERT, CANDACE, RUFF, MICHAEL
Application granted granted Critical
Publication of AU2006261133B2 publication Critical patent/AU2006261133B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AU2006261133A 2005-06-23 2006-06-23 Therapeutic peptides and vaccines Ceased AU2006261133B2 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US69308805P 2005-06-23 2005-06-23
US69308905P 2005-06-23 2005-06-23
US69308705P 2005-06-23 2005-06-23
US60/693,088 2005-06-23
US60/693,089 2005-06-23
US60/693,087 2005-06-23
PCT/US2006/024580 WO2006138745A2 (en) 2005-06-23 2006-06-23 Therapeutic peptides and vaccines

Publications (2)

Publication Number Publication Date
AU2006261133A1 AU2006261133A1 (en) 2006-12-28
AU2006261133B2 true AU2006261133B2 (en) 2012-04-05

Family

ID=37571305

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006261133A Ceased AU2006261133B2 (en) 2005-06-23 2006-06-23 Therapeutic peptides and vaccines

Country Status (9)

Country Link
US (3) US7700115B2 (https=)
EP (1) EP1893233A4 (https=)
JP (1) JP2008546803A (https=)
KR (1) KR20080019720A (https=)
AU (1) AU2006261133B2 (https=)
BR (1) BRPI0611927A2 (https=)
CA (1) CA2624957A1 (https=)
MX (1) MX2007016573A (https=)
WO (1) WO2006138745A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines
US8178497B2 (en) 2007-11-14 2012-05-15 Rapid Pharmaceuticals Ag Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA
US10130674B2 (en) * 2010-02-09 2018-11-20 Creative Bio-Peptides Modified peptide that reduces pain in peripheral neuropathy
US9040046B2 (en) 2011-01-31 2015-05-26 Kai Xu Sodium pump antibody agonists and methods of treating heart disease using the same
US20140092376A1 (en) * 2012-10-01 2014-04-03 Momentive Performance Materials, Inc. Container and method for in-line analysis of protein compositions
US20140322251A1 (en) * 2013-04-26 2014-10-30 Michael Ruff Peptides for Progressive Treating Multi-Focal Leukoencephalopathy and Related Conditions
US20180344798A1 (en) * 2017-05-31 2018-12-06 Creative Bio-Peptides Inc. Topically active peptides for treating cosmetic and dermatological conditions
USRE50630E1 (en) 2017-10-31 2025-10-14 Creative BioPeptides, Inc. Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain
US11510961B2 (en) 2019-12-19 2022-11-29 Creative Bio-Peptides, Inc. Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof
US20210244788A1 (en) * 2020-02-06 2021-08-12 Creative Bio-Peptides Inc. Oral peptide antagonists of multiple chemokine receptors for reversing loss of synapses and dendritic spines

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
WO1987007613A1 (en) * 1986-06-03 1987-12-17 United States Of America, Represented By The Secre Small peptides which inhibit binding to t-4 receptors and act as immunogens
US5863718A (en) * 1986-06-03 1999-01-26 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit to T-4 receptors and act as immunogens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987007614A1 (en) * 1986-06-03 1987-12-17 Pert Candace B Small peptides which inhibit binding to t-4 receptors
US6242564B1 (en) 1986-06-03 2001-06-05 Candace B. Pert Treatment of tropical spastic paresis with peptide T
US5063206A (en) 1988-12-16 1991-11-05 The United States Of Americas As Represented By The Department Of Health And Human Services Compositions having use as treatment of neuropsychiatric deficits
US5739109A (en) 1988-12-16 1998-04-14 Advanced Immunit Inc. Method of treating neuroinflammatory degenerative diseases
DK64592D0 (da) 1992-05-14 1992-05-14 Carlbiotech Ltd As Peptider til terapeutisk behandling
US6011014A (en) 1992-03-27 2000-01-04 Advanced Immunit, Inc. Peptide T and related peptides in the treatment of inflammation, including multiple sclerosis
US5534495A (en) 1993-05-25 1996-07-09 Advanced Peptides And Biotechnology Sciences Treatment of non-HIV neuropathic pain syndromes
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US20040126811A1 (en) * 2002-02-21 2004-07-01 Thomas Boren Helicobacter pylori sialic acid binding adhesin, saba and saba-gene
US7390788B2 (en) 2005-06-23 2008-06-24 Pert Candace B Peptide pharmaceutical compositions
AU2006261133B2 (en) 2005-06-23 2012-04-05 Rapid Pharmaceuticals Ag Therapeutic peptides and vaccines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002775A1 (en) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Synthetic peptides and use for diagnosis and vaccination for aids and arc
WO1987007613A1 (en) * 1986-06-03 1987-12-17 United States Of America, Represented By The Secre Small peptides which inhibit binding to t-4 receptors and act as immunogens
US5863718A (en) * 1986-06-03 1999-01-26 The United States Of America As Represented By The Department Of Health And Human Services Small peptides which inhibit to T-4 receptors and act as immunogens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ruff et al Current HIV Research, 2003:1:51-67. *

Also Published As

Publication number Publication date
US20100184705A1 (en) 2010-07-22
EP1893233A2 (en) 2008-03-05
JP2008546803A (ja) 2008-12-25
EP1893233A4 (en) 2010-03-31
CA2624957A1 (en) 2006-12-28
US10973906B2 (en) 2021-04-13
AU2006261133A1 (en) 2006-12-28
KR20080019720A (ko) 2008-03-04
BRPI0611927A2 (pt) 2011-08-16
US10071153B2 (en) 2018-09-11
MX2007016573A (es) 2008-10-17
US7700115B2 (en) 2010-04-20
US20060292167A1 (en) 2006-12-28
WO2006138745A2 (en) 2006-12-28
US20190000964A1 (en) 2019-01-03
WO2006138745A3 (en) 2007-11-29

Similar Documents

Publication Publication Date Title
US10973906B2 (en) Therapeutic peptides and vaccines
Koch et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition
Root et al. HIV-1 gp41 as a target for viral entry inhibition
Naidu et al. Characterization of infectious molecular clones of simian immunodeficiency virus (SIVmac) and human immunodeficiency virus type 2: persistent infection of rhesus monkeys with molecularly cloned SIVmac
Yuan et al. Characterization of the multiple conformational States of free monomeric and trimeric human immunodeficiency virus envelope glycoproteins after fixation by cross-linker
US8173767B2 (en) Synthetic peptide vaccines for HIV: the CBD epitope as an effective immunogen to elicit broadly neutralizing antibodies against HIV
US7371846B2 (en) CD4-independent HIV envelope proteins as vaccines and therapeutics
Lagenaur et al. sCD4-17b bifunctional protein: extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates
Shibata et al. Impact of V2 mutations on escape from a potent neutralizing anti-V3 monoclonal antibody during in vitro selection of a primary human immunodeficiency virus type 1 isolate
WO1998000535A2 (en) Method for inhibiting hiv-1 infection, drug screens, and methods of diagnosis and prognosis of susceptibility to hiv infection
AU731975B2 (en) GP120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting HIV infection
WO1998015569A9 (en) Gp120 polypeptides having conformational discontinuous chemokine receptor binding sites and methods of inhibiting hiv infection
CN101242854A (zh) 治疗肽及疫苗
US7524927B2 (en) Compositions, method and kits relating to deletion mutations of immunodeficiency virus gp120 hypervariable regions
Matsumi et al. Neutralizing monoclonal antibody against an external envelope glycoprotein (gp110) of SIVmac251
Guenaga Epitope Scaffolds And The HIV-1 gp41 2F5 Neutralization Determinant
Mörner Studies on HIV-2 antibody mediated neutralisation, coreceptor usage and in vivo tropism
LaCasse Part 1. HIV-1 binding and entry events: Implications for vaccine strategies. Part 2. The effects of AZT on the relative mutation frequency of FIV
Suphaphiphat et al. CCR5 coreceptor utilization by human immunodeficiency virus type I subtype E gpl20 involves conserved V3 loop domains
Langhammer Neutralisierende Antikörper gegen die transmembranen Hüllproteine von Retroviren
Biscone The conserved coreceptor binding site and the 3rd hypervariable loop of HIV
Beirnaert Broad cross-neutralisation in HIV-infected individuals
Hoffman Structure-function studies of HIV-1 envelope protein
Nunberg et al. Coreceptor Utilization by Human
HK1072264B (en) Synthetic peptide vaccines for hiv: the cbd epitope as an effective immunogen to elicit broadly neutralizing antibodies against hiv

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: RAPID PHARMACEUTICALS AG

Free format text: FORMER APPLICANT(S): PERT, CANDACE; RUFF, MICHAEL

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired